Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of Novartis meningococcal B recombinant vaccine persistence and booster response in toddlers and young children
2009-018101-52Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal group B vaccine (recombinant, adsorbed) in meningococcal disease (5 arms), sponsored by Novartis. Primary endpoints: Immunogenicity endpoints and Safety and tolerability. Started Apr 2010; status: completed.
02
Drugs
meningococcal group B vaccine (recombinant, adsorbed)
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2009-018101-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018101-52.